The HTAC recommends the DOH financing and inclusion of Covaxin in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP) for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter continue reading : HTAC Guidance for Health Care Providers: COVID-19 Vaccine Covaxin
HTAC Guidance for Health Care Providers: COVID-19 Vaccine Sinopharm
The HTAC recommends the DOH financing and inclusion of Sinopharm in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP) for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter period continue reading : HTAC Guidance for Health Care Providers: COVID-19 Vaccine Sinopharm
HTAC Guidance for Health Care Providers: COVID-19 Vaccine Covovax
The HTAC recommends the DOH financing and inclusion of Covovax in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP) for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter continue reading : HTAC Guidance for Health Care Providers: COVID-19 Vaccine Covovax
HTAC Guidance for Health Care Providers: COVID-19 Vaccine Sputnik V
The HTAC retains its recommendation for DOH to finance and include Sputnik V in the Philippine National Deployment and Vaccination Plan for COVID-19 for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a continue reading : HTAC Guidance for Health Care Providers: COVID-19 Vaccine Sputnik V
Use of Casirivimab + Imdevimab for the Treatment of COVID-19
HTAC interim recommendation on the use of casirivimab+imdevimab for the treatment of COVID-19 On 24 December 2021, the Secretary of Health approved and signed the Health Technology Assessment Council (HTAC) interim recommendation for the government not to finance casirivimab+imdevimab for the treatment of COVID-19. The Philippine Food and Drug Administration (FDA) issued an Emergency Use Authorization continue reading : Use of Casirivimab + Imdevimab for the Treatment of COVID-19